JPH04182426A - Agent for suppressing lipoprotein (a) - Google Patents
Agent for suppressing lipoprotein (a)Info
- Publication number
- JPH04182426A JPH04182426A JP31201090A JP31201090A JPH04182426A JP H04182426 A JPH04182426 A JP H04182426A JP 31201090 A JP31201090 A JP 31201090A JP 31201090 A JP31201090 A JP 31201090A JP H04182426 A JPH04182426 A JP H04182426A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- icosapent
- agent
- ester
- lipoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010033266 Lipoprotein(a) Proteins 0.000 title claims abstract description 8
- 102000057248 Lipoprotein(a) Human genes 0.000 title claims abstract 6
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 24
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 13
- 229930195729 fatty acid Natural products 0.000 claims abstract description 13
- 239000000194 fatty acid Substances 0.000 claims abstract description 13
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 13
- 150000002148 esters Chemical class 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims description 33
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims description 20
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 9
- 125000004494 ethyl ester group Chemical group 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 23
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract description 10
- 229940114079 arachidonic acid Drugs 0.000 abstract description 5
- 235000021342 arachidonic acid Nutrition 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 201000004810 Vascular dementia Diseases 0.000 abstract description 4
- 208000007474 aortic aneurysm Diseases 0.000 abstract description 4
- 206010008118 cerebral infarction Diseases 0.000 abstract description 4
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 4
- 210000004351 coronary vessel Anatomy 0.000 abstract description 4
- 208000037803 restenosis Diseases 0.000 abstract description 4
- 208000018737 Parkinson disease Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 206010067116 Carotid arteriosclerosis Diseases 0.000 abstract 1
- 230000001565 angiopathic effect Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 30
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 11
- 235000021323 fish oil Nutrition 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 4
- 229960002600 icosapent ethyl Drugs 0.000 description 4
- 208000034189 Sclerosis Diseases 0.000 description 3
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000003939 benzylamines Chemical class 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- BJNARTXTPVWSGJ-SRGMUBKESA-N (2E,4E,6E,8E)-hexadeca-2,4,6,8-tetraenoic acid Chemical compound CCCCCCC\C=C\C=C\C=C\C=C\C(O)=O BJNARTXTPVWSGJ-SRGMUBKESA-N 0.000 description 1
- LGHXTTIAZFVCCU-SSVNFBSYSA-N (2E,4E,6E,8E)-octadeca-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O LGHXTTIAZFVCCU-SSVNFBSYSA-N 0.000 description 1
- OOJGMLFHAQOYIL-SQIWNDBBSA-N (2e,4e)-hexadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C(O)=O OOJGMLFHAQOYIL-SQIWNDBBSA-N 0.000 description 1
- SZQQHKQCCBDXCG-BAHYSTIISA-N (2e,4e,6e)-hexadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C(O)=O SZQQHKQCCBDXCG-BAHYSTIISA-N 0.000 description 1
- BBWMTEYXFFWPIF-CJBMEHDJSA-N (2e,4e,6e)-icosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C=C\C(O)=O BBWMTEYXFFWPIF-CJBMEHDJSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- SNXPWYFWAZVIAU-UHFFFAOYSA-N arachidonic acid ethyl ester Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)OCC SNXPWYFWAZVIAU-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001944 continuous distillation Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000001664 diethylamino group Chemical class [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- ATNNLHXCRAAGJS-UHFFFAOYSA-N docos-2-enoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC=CC(O)=O ATNNLHXCRAAGJS-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- SNXPWYFWAZVIAU-GKFVBPDJSA-N ethyl arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCC SNXPWYFWAZVIAU-GKFVBPDJSA-N 0.000 description 1
- FKMJHNHXXLJNTH-UHFFFAOYSA-N ethyl icosa-2,4,6,8-tetraenoate Chemical compound CCCCCCCCCCCC=CC=CC=CC=CC(=O)OCC FKMJHNHXXLJNTH-UHFFFAOYSA-N 0.000 description 1
- GIODNRPAARSHAH-UHFFFAOYSA-N ethyl octadeca-2,4,6,8-tetraenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC(=O)OCC GIODNRPAARSHAH-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- -1 sodium salts Chemical class 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960000912 stanozolol Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は、有効成分としてイコサペント酸、その製薬学
上許容しうる塩およびエズテルからなる群から選ばれる
少なくとも1つを含有するリポプロテイン(a)(以下
Lp (a)ということがある。)低下剤に関するもの
である。Detailed Description of the Invention [Industrial Application Field] The present invention provides a lipoprotein (a ) (hereinafter sometimes referred to as Lp (a)) relates to a lowering agent.
イコサペント酸とは、all−cis−5,8,11,
14,17−icosapentaenoic aci
dである。Icosapentoic acid is all-cis-5,8,11,
14,17-icosapentaenoic aci
It is d.
[従来の技術および発明が解決しようとする課題]
血清Lp (a)はコレステロールに冨み、カルシウム
存在下で凝集しやすく、グリコサミノグリカン等の結合
織成分と結合しやすいため動脈壁への脂質沈着を起こす
可能性が指摘されている(野間昭夫ら、動脈硬化、17
巻、639〜658頁、1989年)。また、グリコサ
ミノグリカン等と結合したLp (a)はマクロファー
ジに取り込まれやすくなり、泡沫細胞化の促進に働く可
能性がある。さらに、Lp (a)に特有なアポ蛋白の
アポ(a)はプラスミノーゲンとの相同性が高((Ka
radi、 I 、ら、Biochemi。[Prior Art and Problems to be Solved by the Invention] Serum Lp(a) is rich in cholesterol, tends to aggregate in the presence of calcium, and easily binds to connective tissue components such as glycosaminoglycans, so it does not reach the arterial wall. It has been pointed out that there is a possibility of causing lipid deposition (Akio Noma et al., Arteriosclerosis, 17
Vol., pp. 639-658, 1989). Furthermore, Lp(a) bound to glycosaminoglycan etc. is easily taken up by macrophages and may work to promote foam cell formation. Furthermore, apo(a), an apoprotein unique to Lp(a), has high homology with plasminogen ((Ka
radi, I., et al., Biochemi.
Biophys、 Acta、、 960 巻、91
〜97頁、1988年)、線溶機構を抑制することが示
唆されている(Edelberg、 J、M、 ら、
Biochemistry、 28巻、2370〜2
374頁、1989年、Hajjar、 K、A、ら、
Nature、 339巻、303〜305頁、198
9年)。これらのことは、Lp (a)が動脈硬化の発
症、進展に働くことを示唆すると考えられる。実際、L
p (a)は虚血性心疾患、冠動脈バイパス手術後の再
狭窄、脳梗塞、頚動脈硬化、腹部大動脈瘤、血管性痴呆
、糖尿病、糖尿病性網膜症および血管障害性のパーキン
ソン病等に対して、従来の低比重リポプロテインコレス
テロールや血小板凝集などとは異なる独立した危険因子
と考えられている(野間昭夫ら、動脈硬化、17巻、6
39〜658頁、1989年)。Biophys, Acta, Volume 960, 91
~97, 1988) and has been suggested to suppress the fibrinolytic mechanism (Edelberg, J. M., et al.
Biochemistry, Volume 28, 2370-2
374 pages, 1989, Hajjar, K. A. et al.
Nature, vol. 339, pp. 303-305, 198
9 years). These results are considered to suggest that Lp(a) acts on the onset and progression of arteriosclerosis. In fact, L
p (a) is for ischemic heart disease, restenosis after coronary artery bypass surgery, cerebral infarction, carotid artery sclerosis, abdominal aortic aneurysm, vascular dementia, diabetes, diabetic retinopathy, and vasculopathic Parkinson's disease, etc. It is considered to be an independent risk factor different from conventional low-density lipoprotein cholesterol and platelet aggregation (Akio Noma et al., Arteriosclerosis, Vol. 17, 6).
39-658, 1989).
一方、従来の高脂血症治療剤は血漿脂質のうち、主に低
比重リボ蛋白コレステロールおよびトリグリセリドの低
下作用に着目された薬剤であり、Lp (a)への作用
はほとんど注目されていなかった。近年、従来の高脂血
症治療剤のLp (a)に対する作用について以下のよ
うな報告がある。高脂血症治療剤として公知であるプロ
ブコール(Maeda、 S 、ら、Atherosc
lerosis 、79巻、 267〜269 頁、
1989年)、クロフィブレート(Albers、
J。On the other hand, conventional antihyperlipidemia drugs have focused on lowering low-density riboprotein cholesterol and triglycerides among plasma lipids, and little attention has been paid to their effects on Lp(a). . In recent years, the following reports have been made regarding the effects of conventional hyperlipidemia therapeutic agents on Lp(a). Probucol (Maeda, S., et al., Atherosc.
lerosis, volume 79, pages 267-269,
1989), clofibrate (Albers,
J.
ら、Metabolism、 24巻、1047〜1
054頁、 197’年)、コレスチラミン(Ler
en、 T、P、 ら、Atherosclero
sis 、 73巻、135〜141 頁、1988
年)、ブラバスタチン(Jacob、 B、G、ら、A
nn。et al., Metabolism, vol. 24, 1047-1
054, 197'), cholestyramine (Ler
en, T.P., et al., Atherosclero
sis, vol. 73, pp. 135-141, 1988
), bravastatin (Jacob, B, G, et al., A
nn.
Intern、 Medl、112 巻、713〜7
14 頁、1990年)、ロバスタチン、シンパスタチ
ン(Kostner、 G、M、ら、C1rcula
tion 、 80巻、1313〜1319頁、19
89年)およびエブタスタチン(村井淳志ら、動脈硬化
、15巻、1461−1464頁、1987年)等は血
清Lp (a)低下作用を有さず、むしろ上昇傾向を示
す例すらある。わずかにニコチン酸製剤(Carlso
n、 L、A、ら、J。Intern, Medl, vol. 112, 713-7
14, 1990), lovastatin, simpastatin (Kostner, G, M, et al., C1rcula
tion, vol. 80, pp. 1313-1319, 19
1989) and ebtastatin (Atsushi Murai et al., Arteriosclerosis, Vol. 15, pp. 1461-1464, 1987), etc., do not have an effect of lowering serum Lp(a), and in some cases even tend to increase it. Slightly nicotinic acid preparations (Carlso
n, L, A, et al., J.
Intern、 Med、 、 226巻、271〜2
76頁、1989年)、ベザフィプレート(Schwa
rtzkopff、 W。Intern, Med, 226, 271-2
76 pages, 1989), Bezafi Plate (Schwa
rtzkopff, W.
ら、Muench、 Med、 Wochensc
hr、、 130 巻、422〜426頁、1988
年)などに血清Lp (a)低下作用が認められている
にすぎない。また、ステロイド剤であるスタノゾロール
(Albers。et al., Muench, Med, Wochensc.
hr, vol. 130, pp. 422-426, 1988
Only a serum Lp(a)-lowering effect has been observed in patients such as 2010). Also, the steroid drug Stanozolol (Albers).
J、ら、Biochemica Biophysic
a Acta、 。J. et al. Biochemica Biophysics
a Acta, .
795 巻、293 〜296 頁、1984年)
、抗生物質であるネオマイシン(Gurakar、 A
、ら、Atherosclerosis 、 57巻
、293〜301頁、1985年)に血清Lp (a)
低下作用が認められているが、副作用等の面で問題があ
る。795, pp. 293-296, 1984)
, the antibiotic neomycin (Gurakar, A
, et al., Atherosclerosis, Vol. 57, pp. 293-301, 1985) in serum Lp(a).
Although it has been shown to have a lowering effect, there are problems in terms of side effects, etc.
魚油あるいはイコサペント酸およびドコサヘキサエン酸
を含む魚肝油等の健康食品の血清しp (a)低下作用
に関する報告もされているが、Lp (a)を低下させ
たとする報告(Gavish。There have been reports on the serum Lp(a) lowering effect of health foods such as fish oil or fish liver oil containing icosapentoic acid and docosahexaenoic acid; however, there have been reports that they lower Lp(a) (Gavish).
D、ら、Cl1n、Res、、38巻、250A頁、1
990年)、作用なしとする報告(Gries、 A
、ら、Thrombosis Res、 、 58
巻、667〜668頁、1990年)および運動負荷と
の併用で一部の患者のLp (a)を低下させたとする
報告(Herrmann。D, et al., Cl1n, Res, vol. 38, p. 250A, 1
990), report of no effect (Gries, A.
, et al., Thrombosis Res, , 58
Vol., pp. 667-668, 1990) and a report that Lp(a) was lowered in some patients when combined with exercise stress (Herrmann et al.).
W、ら、Med、 K11n、、 84巻、429〜4
33頁、1989年)等、相反する結果が得られている
。また、仮に魚油がLp (a)低下作用をあられすと
しても、これまでの知見では有効成分が何であるのかま
ったくわかつておらず、脂肪酸や他のビタミン等が作用
している可能性もある。W, et al., Med, K11n, 84, 429-4.
33, 1989), contradictory results have been obtained. Furthermore, even if fish oil were to have an Lp(a)-lowering effect, it is not clear at all what the active ingredient is based on the knowledge to date, and it is possible that fatty acids or other vitamins are at play.
さらに、魚油や健康食品についてはいずれもイコサペン
ト酸含有量が低く、血小板凝集作用等を有するトロンボ
キサンA2や白血球遊走作用を有するロイコトリエンB
4の前駆体であるアラキドン酸なども含まれる。また、
魚油や健康食品で有効性を高めるためにその投与量を上
げると、脂肪酸によるカロリー過多やビタミンA、Dを
過剰に摂取する等の危険性があり、さらに、悪心、嘔吐
、下痢、腹痛および体重増加等の副作用発現率も高い(
Re1s、 G、 J、 。Furthermore, fish oil and health foods both have low icosapent acid content, including thromboxane A2, which has platelet aggregation properties, and leukotriene B, which has leukocyte migration properties.
Arachidonic acid, which is a precursor of No. 4, is also included. Also,
If you increase the dosage of fish oil or health foods to increase their effectiveness, you run the risk of consuming too many calories from fatty acids and taking too much vitamins A and D, and may also cause nausea, vomiting, diarrhea, abdominal pain, and weight loss. There is also a high incidence of side effects such as increased
Re1s, G., J.
Lancet、 Aug 31. 2 巻、8656
号、177〜181頁、1989年)。Lancet, Aug. 31. Volume 2, 8656
No., pp. 177-181, 1989).
魚油中のイコサペント酸に注目してみると、これは血清
総コレステロールおよびトリグリセリド低下作用を有す
ることが知られている。また、イコサペント酸、その塩
、エステルまたはアミドな高純度含有する血栓症治療ま
たは予防のための処方物が特公昭62−57605に開
示されている。また、高純度イコサペント酸エチル製剤
であるエバゾール■(持出製薬)投与による副作用発現
率は低いことが知られている(0.H,P、学術情報委
員会、0.H,P、news。Focusing on icosapentoic acid in fish oil, it is known to have a serum total cholesterol and triglyceride lowering effect. Further, a formulation for the treatment or prevention of thrombosis containing highly purified icosapentic acid, its salt, ester or amide is disclosed in Japanese Patent Publication No. 62-57605. Furthermore, it is known that the incidence of side effects is low when administered with Evasol ■ (Kokado Seiyaku), a highly purified ethyl icosapentate preparation (0.H,P, Academic Information Committee, 0.H,P, news).
32巻、205〜208頁、1990年)。しかし、イ
コサペント酸、その塩もしくはエステルのLp(a)に
対する作用についての知見は現在までない。32, pp. 205-208, 1990). However, to date, there is no knowledge regarding the effect of icosapent acid, its salts or esters on Lp(a).
以上のことからもわかるように、血清Lp(a)は食餌
や薬物の影響を受けに(いことが知られている。このた
め、血清Lp (a)低下作用を有し、かつ安全に投与
できる薬剤の開発が切望されている。As can be seen from the above, it is known that serum Lp(a) is not affected by diet or drugs. Therefore, it has a serum Lp(a) lowering effect and can be administered safely. The development of drugs that can do this is desperately needed.
[課題を解決するための手段]
本発明者らは、上記課題を解決するため鋭意研究を行っ
た結果、イコサペント酸に血清Lp(a)低下作用を見
いだし、本発明を完成した。[Means for Solving the Problems] As a result of intensive research to solve the above problems, the present inventors discovered that icosapentoic acid has a serum Lp(a) lowering effect, and completed the present invention.
すなわち本発明は、有効成分としてイコサペント酸、そ
の製薬挙上許容しうる塩およびエステルからなる群から
選ばれる少なくとも1つを含有するリポプロテイン(a
)低下剤である。That is, the present invention provides a lipoprotein (a
) is a depressant.
この有効成分にさらにイコサペント酸以外の脂肪酸を含
有してもよく、全脂肪酸中のイコサペント酸の含有量は
少なくとも50重量%であるのが好ましい。The active ingredient may further contain fatty acids other than icosapent acid, and the content of icosapent acid in the total fatty acids is preferably at least 50% by weight.
また、有効成分として、イコサペント酸エチルエステル
が好ましい。Moreover, as an active ingredient, icosapent acid ethyl ester is preferable.
以下に本発明の詳細な説明する。The present invention will be explained in detail below.
本発明のLp (a)低下剤は、有効成分としてイコサ
ペント酸、その製薬挙上許容しうる塩、エステルもしく
はこれらの混合物を含有する。The Lp(a) lowering agent of the present invention contains icosapent acid, its pharmaceutically acceptable salts, esters or mixtures thereof as an active ingredient.
本発明のLp (a)低下剤中のイコサペント酸は、エ
チルエステル等のアルキルエステルまたはグリセリド等
の製薬挙上許容されるエステルとすることができる。ま
た、ナトリウム塩、カリウム塩等の無機塩基またはベン
ジルアミン塩、ジエチルアミン塩等の有機塩基あるいは
アルギニン塩、リジン塩等の塩基性アミノ酸との製薬挙
上許容される塩を形成することもできる。The icosapentoic acid in the Lp(a) lowering agent of the present invention can be an alkyl ester such as an ethyl ester or a pharmaceutically acceptable ester such as a glyceride. It is also possible to form pharmaceutically acceptable salts with inorganic bases such as sodium salts and potassium salts, organic bases such as benzylamine salts and diethylamine salts, or basic amino acids such as arginine salts and lysine salts.
本発明の低下剤は、さらに、イコサペント酸以外の脂肪
酸を含有してもよい。 これらの脂肪酸は、ドコサヘキ
サエン酸、ドコサベンクエン酸、ドコサモノエン酸、ア
ラキドン酸、エイコサテトラエン酸、エイコサトリエン
酸、エイコサモノエン酸、オクタデカテトラエン酸、α
−リルン酸、リノール酸、オレイン酸、パルミトオレイ
ン酸、ヘキサデカテトラエン酸、ヘキサデカトリエン酸
およびヘキサデカジエン酸等の不飽和脂肪酸あるいはベ
ヘン酸、アラキシン酸、ステアリン酸、パルミチン酸お
よびミリスチン酸等の飽和脂肪酸等が例示される。The lowering agent of the present invention may further contain fatty acids other than icosapent acid. These fatty acids include docosahexaenoic acid, docosabencitric acid, docosamonoenoic acid, arachidonic acid, eicosatetraenoic acid, eicosatrienoic acid, eicosamonenoic acid, octadecatetraenoic acid, alpha
- Unsaturated fatty acids such as lylunic acid, linoleic acid, oleic acid, palmitoleic acid, hexadecatetraenoic acid, hexadecatrienoic acid and hexadecadienoic acid or behenic acid, alaxic acid, stearic acid, palmitic acid and myristic acid. Examples include saturated fatty acids such as
また、本発明でいうイコサペント酸をはじめとする脂肪
酸とは特に断らない限り、上述の例の脂肪酸の遊離体の
ほか、それらのナトリウム塩等の無機塩基との塩または
ベンジルアミン塩等の有機塩基との塩、さらにはそれら
のエチルエステル等のアルキルエステルまたはグリセリ
ド等のエステル体を意味する。In addition, unless otherwise specified, fatty acids such as icosapentoic acid as used in the present invention refer to free forms of fatty acids such as those mentioned above, salts thereof with inorganic bases such as sodium salts, or organic bases such as benzylamine salts. and their alkyl esters such as ethyl ester, or esters thereof such as glycerides.
本発明のLp (a)低下剤の全脂肪酸中のイコサペン
ト酸は50重量%以上、好ましくは70重量%以上であ
り、さらに好ましくは90重量%以上であり、アラキド
ン酸含量は少ないことが望まれる。It is desirable that the icosapent acid content in the total fatty acids of the Lp (a) lowering agent of the present invention is 50% by weight or more, preferably 70% by weight or more, more preferably 90% by weight or more, and the arachidonic acid content is low. .
このようなイコサペント酸あるいはそのエステルは、例
えば魚油などの天然油脂より連続式蒸留法や液体クロマ
トグラフィー法等により得ることができる。イコサペン
ト酸は、イコサペント酸エステルを既知の方法により加
水分解する事によって得る事もできる。あるいは既存の
市販品1例えば、純度約98%のイコサペント酸、純度
約98%のイコサペント酸ナトリウム塩、純度約99%
のイコサペント酸メチルエステル(以上シグマケミカル
社製)、純度90%以上のイコサペント酸(アルドリッ
チケミカル社製、ナカライテスク社製およびフルカケミ
カバイオケミカ社製)、純度95%以上のイコサペント
酸(フナコシ薬品社製)および純度90%のイコサペン
ト酸エチルエステル(東京化成工業社製)等を用いるこ
とができる。Such icosapent acid or its ester can be obtained, for example, from natural fats and oils such as fish oil by continuous distillation, liquid chromatography, and the like. Icosapent acid can also be obtained by hydrolyzing icosapent acid ester by known methods. Or existing commercially available products 1 For example, icosapent acid with a purity of about 98%, icosapent acid sodium salt with a purity of about 98%, purity of about 99%
Icosapentoic acid methyl ester of (manufactured by Tokyo Kasei Kogyo Co., Ltd.) and icosapent acid ethyl ester (manufactured by Tokyo Kasei Kogyo Co., Ltd.) with a purity of 90% can be used.
本発明のLp (a)低下剤の成人1日当たりの治療量
は、イコサペント酸として0.5ないし5.0gである
が、投与経路あるいは症状により適宜増減することがで
き、全量を一度に投与することや分割して投与すること
も可能である。投与経路としては、経口投与が好ましい
が、静脈内、直腸内投与の他、外用剤としても使用可能
であり、軟カプセル剤、錠剤および乳剤などの単位投与
形態を取り得る。The daily therapeutic dose for an adult of the Lp (a) lowering agent of the present invention is 0.5 to 5.0 g as icosapentoic acid, but it can be increased or decreased as appropriate depending on the route of administration or symptoms, and the entire amount can be administered at once. It is also possible to administer separately or in divided doses. As for the route of administration, oral administration is preferred, but in addition to intravenous and rectal administration, it can also be used as an external preparation, and can take unit dosage forms such as soft capsules, tablets, and emulsions.
以下、本発明のLp (a)低下剤の有効性、安全性、
および治療剤の製法について述べる。Hereinafter, the effectiveness, safety, and
and methods for producing therapeutic agents.
血清Lp(a)濃度に対する作用
正脂血症者および高脂血症者合わせて6名に、エバゾー
ル■を2.7g/日経口投与し、投与前、投与後4およ
び122週目採血し血清Lp (a)値をバイオブール
社製のプレートを使用した酵素免疫測定法で測定した。Effect on serum Lp(a) concentration 2.7 g/day of Evazol was orally administered to a total of 6 subjects with dyslipidemia and hyperlipidemia, and blood samples were collected before administration, 4 and 122 weeks after administration, and serum samples were collected. The Lp(a) value was measured by enzyme immunoassay using a plate manufactured by Bioboule.
第1表に結果を示す。Table 1 shows the results.
に及ぼす影響
以上のように、エバゾール■12週間連続経口投与によ
り、特に高いLp (a)値の人を含めて金側でLp
(a)の著しい低下作用が認められた。この作用はほと
んどの人で4週目から認められた。また、投与期間中顕
著な副作用は認められなかった。As mentioned above, continuous oral administration of Evazol ■ for 12 weeks lowers Lp on the gold side, including in people with particularly high Lp(a) values.
A significant reduction in (a) was observed. This effect was observed from the 4th week onwards in most people. Furthermore, no significant side effects were observed during the administration period.
エバゾール■は安全性が高いことが知られており、毒性
試験に関しては、次の文献に記載がある。渋谷端義ら、
医薬品研究、20巻、801〜844頁、1989年。Evasol ■ is known to be highly safe, and toxicity tests are described in the following literature. Danyoshi Shibuya et al.
Pharmaceutical Research, Vol. 20, pp. 801-844, 1989.
また、イコサペント酸およびトリグリセリド型イコサペ
ント酸も同様に高い安全性を有する。In addition, icosapent acid and triglyceride type icosapent acid have high safety as well.
以上の説明および試験結果より明らかなように、本発明
Lp (a)低下剤は著明なLp(a)低下作用を有し
、安全性も高いことから、Lp (a)低下剤として有
用である。また、Lp (a)が危険因子と考えられて
いる疾患、例えば、虚血性心疾患、冠動脈バイパス手術
後の再狭窄、脳梗塞、頚動脈硬化、腹部大動脈瘤、血管
性痴呆、糖尿病、糖尿病性網膜症および血管障害性のパ
ーキンソン病等の予防および治療にも有効である
また、本発明のLp (a)低下剤は、任意、慣用の製
薬用担体、基剤あるいは賦形剤とともに慣用の方法で、
医薬製剤に調製することができる。As is clear from the above explanation and test results, the Lp(a) lowering agent of the present invention has a remarkable Lp(a) lowering effect and is highly safe, so it is useful as an Lp(a) lowering agent. be. In addition, diseases for which Lp(a) is considered a risk factor, such as ischemic heart disease, restenosis after coronary artery bypass surgery, cerebral infarction, carotid artery sclerosis, abdominal aortic aneurysm, vascular dementia, diabetes, and diabetic retina. In addition, the Lp(a) lowering agent of the present invention can be used with any conventional pharmaceutical carrier, base, or excipient in a conventional manner. ,
It can be prepared into pharmaceutical formulations.
次に製剤の実施例を示すが、本発明は以下の実施例に限
定されるものではない。Next, examples of formulations will be shown, but the present invention is not limited to the following examples.
実施例A 軟カプセル剤
軟質ゼラチンカプセル(約0.5ml容)を滅菌し、エ
チル化および精製した魚油、すなわちイコサペント酸エ
チル90.6%、アラキドン酸エチル2.3%、オクタ
デカテトラエン酸エチル2.2%、ω−3イコサテトラ
エン酸エチル0.7%を含む組成物にビタミンEを0.
2%となるように加えて、イコサペント酸エチルとして
300mgとなるように満たし、次いで封じた。Example A Soft Capsules Soft gelatin capsules (approximately 0.5 ml volume) are sterilized, ethylated and purified fish oil: 90.6% ethyl icosapentate, 2.3% ethyl arachidonate, ethyl octadecatetraenoate. 0.2% of vitamin E and 0.7% of ω-3 ethyl icosatetraenoate.
The solution was added to 2% and filled with 300 mg of ethyl icosapentate, and then sealed.
実施例B 乳剤
イコサペント酸エチル 11
流動パラフイン 9
ミリスチン酸イソプロピル 5
セタノール 5モノステアリン
酸ソルビタン 3.8モノステアリン酸ポリオキシ
エチレンソルビタン 6.2ジブチルヒドロ
キシトルエン 0. 2パラオキシ安息香酸メチル
0.2バラオキシ安息香酸プロピル 0.
1精製水 59.5100重量
%
上記各成分のうち、精製水以外の成分を80℃にて加熱
溶解し、これに80℃に加熱した精製水を撹拌しながら
徐々に加え、10分間乳化させる。その後撹拌しながら
35℃まで冷却し、均一な乳化物を得る。Example B Emulsion Ethyl icosapentate 11 Liquid paraffin 9 Isopropyl myristate 5 Setanol 5 Sorbitan monostearate 3.8 Polyoxyethylene sorbitan monostearate 6.2 Dibutylhydroxytoluene 0. 2 Methyl paraoxybenzoate 0.2 Propyl paraoxybenzoate 0.
1 Purified water 59.5100% by weight Among the above components, the components other than purified water are dissolved by heating at 80° C., and purified water heated to 80° C. is gradually added to this while stirring, and emulsified for 10 minutes. Thereafter, the mixture is cooled to 35° C. while stirring to obtain a uniform emulsion.
[発明の効果]
本発明Lp (a)低下剤は著明なLp (a)低下作
用を有し、また、トリグリセライドリッチリポプロテイ
ン部分に8現するLp (a)も低下させる。これらが
危険因子と考えられている疾患、例えば、虚血性心疾患
、冠動脈バイパス手術後の再狭窄、脳梗塞、頚動脈硬化
、腹部大動脈瘤、血管性痴呆、糖尿病、糖尿病性網膜症
および血管障害性のパーキンソン病等の予防剤および治
療剤として期待される。一方、本発明Lp (a)低下
剤は高純度イコサペント酸を有効成分としたものであり
、アラキドン酸等の不純物含有量が少なく、魚油で認め
られるような副作用がな(高い安全性を有することから
、事実上Lp (a)低下剤として使用し得る初めての
製剤である。[Effects of the Invention] The Lp(a)-lowering agent of the present invention has a remarkable Lp(a)-lowering effect, and also lowers Lp(a) expressed in triglyceride-rich lipoprotein moieties. Diseases for which these are considered risk factors, such as ischemic heart disease, restenosis after coronary artery bypass surgery, cerebral infarction, carotid artery sclerosis, abdominal aortic aneurysm, vascular dementia, diabetes, diabetic retinopathy, and vasculopathy. It is expected to be used as a preventive and therapeutic agent for Parkinson's disease, etc. On the other hand, the Lp (a) lowering agent of the present invention contains high-purity icosapent acid as an active ingredient, has a low content of impurities such as arachidonic acid, and does not have the side effects observed with fish oil (has high safety). This is actually the first formulation that can be used as an Lp(a) lowering agent.
Claims (4)
容しうる塩およびエステルからなる群から選ばれる少な
くとも1つを含有するリポプロテイン(a)低下剤。(1) A lipoprotein (a) lowering agent containing at least one member selected from the group consisting of icosapent acid, its pharmaceutically acceptable salts and esters as an active ingredient.
肪酸、その塩およびエステルを含有する請求項1記載の
リポプロテイン(a)低下剤。(2) The lipoprotein (a) lowering agent according to claim 1, wherein the active ingredient further contains a fatty acid other than icosapent acid, a salt thereof, and an ester.
ル中の少なくとも50重量%である請求項2記載のリポ
プロテイン(a)低下剤。(3) The lipoprotein (a) lowering agent according to claim 2, wherein the active ingredient is at least 50% by weight of the total fatty acids, salts and esters thereof.
ある請求項1ないし3のいずれかに記載のリポプロテイ
ン(a)低下剤。(4) The lipoprotein (a) lowering agent according to any one of claims 1 to 3, wherein the active ingredient is icosapent acid ethyl ester.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP02312010A JP3103588B2 (en) | 1990-11-16 | 1990-11-16 | Lipoprotein (a) lowering agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP02312010A JP3103588B2 (en) | 1990-11-16 | 1990-11-16 | Lipoprotein (a) lowering agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04182426A true JPH04182426A (en) | 1992-06-30 |
JP3103588B2 JP3103588B2 (en) | 2000-10-30 |
Family
ID=18024125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP02312010A Expired - Lifetime JP3103588B2 (en) | 1990-11-16 | 1990-11-16 | Lipoprotein (a) lowering agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3103588B2 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000044361A2 (en) * | 1999-01-27 | 2000-08-03 | Laxdale Limited | Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders |
EP1683519A1 (en) * | 2003-11-14 | 2006-07-26 | Mochida Pharmaceutical Co., Ltd. | Preventive/therapeutic agent for speech disorder |
EP1968402A2 (en) * | 2005-10-07 | 2008-09-17 | Ocean Nutrition Canada Limited | Salts of fatty acids and methods of making and using thereof |
US7439267B2 (en) | 2001-01-25 | 2008-10-21 | Pfizer Italia S.R.L. | Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy |
WO2009142242A1 (en) * | 2008-05-20 | 2009-11-26 | 持田製薬株式会社 | Composition for preventing cardiovascular event in high-risk patient |
US8293727B2 (en) | 2009-02-10 | 2012-10-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US8298554B2 (en) | 2009-04-29 | 2012-10-30 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US8410086B2 (en) | 2009-06-15 | 2013-04-02 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides |
US8691871B2 (en) | 2009-04-29 | 2014-04-08 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US9603826B2 (en) | 2012-06-29 | 2017-03-28 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9827219B2 (en) | 2012-01-06 | 2017-11-28 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10314803B2 (en) | 2008-09-02 | 2019-06-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10493058B2 (en) | 2009-09-23 | 2019-12-03 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
US10537544B2 (en) | 2011-11-07 | 2020-01-21 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10668042B2 (en) | 2018-09-24 | 2020-06-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US10888539B2 (en) | 2013-09-04 | 2021-01-12 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
US11141399B2 (en) | 2012-12-31 | 2021-10-12 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US11179362B2 (en) | 2012-11-06 | 2021-11-23 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11547710B2 (en) | 2013-03-15 | 2023-01-10 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712428B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
-
1990
- 1990-11-16 JP JP02312010A patent/JP3103588B2/en not_active Expired - Lifetime
Cited By (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8188146B2 (en) | 1999-01-27 | 2012-05-29 | Amarin Corporation Plc. | Highly purified ethyl EPA and other EPA derivatives |
WO2000044361A3 (en) * | 1999-01-27 | 2000-12-21 | Laxdale Ltd | Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders |
EP1417963A1 (en) * | 1999-01-27 | 2004-05-12 | Laxdale Limited | Highly purified EPA and derivatives for psychiatric and neurological disorders |
US7119118B2 (en) | 1999-01-27 | 2006-10-10 | Laxdale Limited | Highly purified ethyl EPA and other EPA derivatives for treatment of huntington's disease |
KR100760038B1 (en) * | 1999-01-27 | 2007-10-04 | 애머린 뉴로사이언스 리미티드 | A pharmaceutical preparation for the treatment or prevention of huntington's disease |
WO2000044361A2 (en) * | 1999-01-27 | 2000-08-03 | Laxdale Limited | Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders |
CN100423718C (en) * | 1999-01-27 | 2008-10-08 | 拉克斯戴尔有限公司 | Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders |
US7439267B2 (en) | 2001-01-25 | 2008-10-21 | Pfizer Italia S.R.L. | Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy |
EP1683519A1 (en) * | 2003-11-14 | 2006-07-26 | Mochida Pharmaceutical Co., Ltd. | Preventive/therapeutic agent for speech disorder |
EP1683519A4 (en) * | 2003-11-14 | 2009-04-01 | Mochida Pharm Co Ltd | Preventive/therapeutic agent for speech disorder |
EP1968402A2 (en) * | 2005-10-07 | 2008-09-17 | Ocean Nutrition Canada Limited | Salts of fatty acids and methods of making and using thereof |
JPWO2009142242A1 (en) * | 2008-05-20 | 2011-09-29 | 持田製薬株式会社 | Composition for preventing cardiovascular events in high-risk patients |
WO2009142242A1 (en) * | 2008-05-20 | 2009-11-26 | 持田製薬株式会社 | Composition for preventing cardiovascular event in high-risk patient |
US10314803B2 (en) | 2008-09-02 | 2019-06-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
US8318715B2 (en) | 2009-02-10 | 2012-11-27 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US8426399B2 (en) | 2009-02-10 | 2013-04-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US8314086B2 (en) | 2009-02-10 | 2012-11-20 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US8293728B2 (en) | 2009-02-10 | 2012-10-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US8324195B2 (en) | 2009-02-10 | 2012-12-04 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US8357677B1 (en) | 2009-02-10 | 2013-01-22 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US8367652B2 (en) | 2009-02-10 | 2013-02-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US8377920B2 (en) | 2009-02-10 | 2013-02-19 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US8399446B2 (en) | 2009-02-10 | 2013-03-19 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US8293727B2 (en) | 2009-02-10 | 2012-10-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US8415335B2 (en) | 2009-02-10 | 2013-04-09 | Amarin Pharmaceutical Ireland Limited | Methods of treating hypertriglyceridemia |
US9060983B2 (en) | 2009-04-29 | 2015-06-23 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US11154526B2 (en) | 2009-04-29 | 2021-10-26 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US8445003B2 (en) | 2009-04-29 | 2013-05-21 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US10449172B2 (en) | 2009-04-29 | 2019-10-22 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US8454994B2 (en) | 2009-04-29 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US8501225B2 (en) | 2009-04-29 | 2013-08-06 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US8613945B2 (en) | 2009-04-29 | 2013-12-24 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US8617593B2 (en) | 2009-04-29 | 2013-12-31 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US8691871B2 (en) | 2009-04-29 | 2014-04-08 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US9056088B2 (en) | 2009-04-29 | 2015-06-16 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising fatty acids |
US9060982B2 (en) | 2009-04-29 | 2015-06-23 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US10624870B2 (en) | 2009-04-29 | 2020-04-21 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US9072715B2 (en) | 2009-04-29 | 2015-07-07 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US9138415B2 (en) | 2009-04-29 | 2015-09-22 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US8298554B2 (en) | 2009-04-29 | 2012-10-30 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US10265287B2 (en) | 2009-04-29 | 2019-04-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing triglycerides and LDL-C |
US9585856B2 (en) | 2009-04-29 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US11690820B2 (en) | 2009-04-29 | 2023-07-04 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US10792267B2 (en) | 2009-04-29 | 2020-10-06 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US10220013B2 (en) | 2009-04-29 | 2019-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US11400069B2 (en) | 2009-04-29 | 2022-08-02 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US10842766B2 (en) | 2009-04-29 | 2020-11-24 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US11213504B2 (en) | 2009-04-29 | 2022-01-04 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US8445013B2 (en) | 2009-04-29 | 2013-05-21 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US11147787B2 (en) | 2009-04-29 | 2021-10-19 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US11103477B2 (en) | 2009-04-29 | 2021-08-31 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US11033523B2 (en) | 2009-04-29 | 2021-06-15 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
US10881632B2 (en) | 2009-04-29 | 2021-01-05 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US9855237B2 (en) | 2009-04-29 | 2018-01-02 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US10888537B2 (en) | 2009-04-29 | 2021-01-12 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising omega-3 fatty acids |
US10987331B2 (en) | 2009-04-29 | 2021-04-27 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US10940131B2 (en) | 2009-04-29 | 2021-03-09 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US10010517B2 (en) | 2009-04-29 | 2018-07-03 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US11464757B2 (en) | 2009-06-15 | 2022-10-11 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides |
US8455472B2 (en) | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10842768B2 (en) | 2009-06-15 | 2020-11-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides |
US11439618B2 (en) | 2009-06-15 | 2022-09-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides |
US8410086B2 (en) | 2009-06-15 | 2013-04-02 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides |
US11007173B2 (en) | 2009-09-23 | 2021-05-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
US10493058B2 (en) | 2009-09-23 | 2019-12-03 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
US11712428B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US10632094B2 (en) | 2011-11-07 | 2020-04-28 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US10537544B2 (en) | 2011-11-07 | 2020-01-21 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US10973796B2 (en) | 2012-01-06 | 2021-04-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity C-reactive protein (hs-CRP) in a subject |
US9827219B2 (en) | 2012-01-06 | 2017-11-28 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject |
US10278939B2 (en) | 2012-06-29 | 2019-05-07 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US10278937B2 (en) | 2012-06-29 | 2019-05-07 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US9603826B2 (en) | 2012-06-29 | 2017-03-28 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US9610272B2 (en) | 2012-06-29 | 2017-04-04 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US10278935B2 (en) | 2012-06-29 | 2019-05-07 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US10278936B2 (en) | 2012-06-29 | 2019-05-07 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US10555925B1 (en) | 2012-06-29 | 2020-02-11 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
US10555924B2 (en) | 2012-06-29 | 2020-02-11 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
US9623001B2 (en) | 2012-06-29 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US10568861B1 (en) | 2012-06-29 | 2020-02-25 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
US10576054B1 (en) | 2012-06-29 | 2020-03-03 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
US10016386B2 (en) | 2012-06-29 | 2018-07-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US10278938B2 (en) | 2012-06-29 | 2019-05-07 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US10894028B2 (en) | 2012-06-29 | 2021-01-19 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
US10383840B2 (en) | 2012-06-29 | 2019-08-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
US9918955B2 (en) | 2012-06-29 | 2018-03-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US9693985B2 (en) | 2012-06-29 | 2017-07-04 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US9693984B2 (en) | 2012-06-29 | 2017-07-04 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US9918954B2 (en) | 2012-06-29 | 2018-03-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US10792270B2 (en) | 2012-06-29 | 2020-10-06 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
US9693986B2 (en) | 2012-06-29 | 2017-07-04 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US11179362B2 (en) | 2012-11-06 | 2021-11-23 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US11229618B2 (en) | 2012-11-06 | 2022-01-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US11141399B2 (en) | 2012-12-31 | 2021-10-12 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US11185525B2 (en) | 2013-02-06 | 2021-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US10265290B2 (en) | 2013-02-06 | 2019-04-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US10166209B2 (en) | 2013-02-06 | 2019-01-01 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US10973797B2 (en) | 2013-02-06 | 2021-04-13 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein c-III |
US10610508B2 (en) | 2013-02-06 | 2020-04-07 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US10675263B2 (en) | 2013-02-06 | 2020-06-09 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US10167467B2 (en) | 2013-02-13 | 2019-01-01 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US10851374B2 (en) | 2013-02-13 | 2020-12-01 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9855240B2 (en) | 2013-02-19 | 2018-01-02 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US10206898B2 (en) | 2013-03-14 | 2019-02-19 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US11547710B2 (en) | 2013-03-15 | 2023-01-10 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US10888539B2 (en) | 2013-09-04 | 2021-01-12 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US10292959B2 (en) | 2013-10-10 | 2019-05-21 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10722485B2 (en) | 2013-10-10 | 2020-07-28 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US11285127B2 (en) | 2013-10-10 | 2022-03-29 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US11052063B2 (en) | 2014-06-11 | 2021-07-06 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US11446269B2 (en) | 2014-06-16 | 2022-09-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10842765B2 (en) | 2016-03-15 | 2020-11-24 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
US11116743B2 (en) | 2018-09-24 | 2021-09-14 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US11116742B2 (en) | 2018-09-24 | 2021-09-14 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US11369582B2 (en) | 2018-09-24 | 2022-06-28 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US11298333B1 (en) | 2018-09-24 | 2022-04-12 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US10786478B2 (en) | 2018-09-24 | 2020-09-29 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US10668042B2 (en) | 2018-09-24 | 2020-06-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US11000499B2 (en) | 2018-09-24 | 2021-05-11 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US11717504B2 (en) | 2018-09-24 | 2023-08-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
Also Published As
Publication number | Publication date |
---|---|
JP3103588B2 (en) | 2000-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH04182426A (en) | Agent for suppressing lipoprotein (a) | |
US20210205254A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
JP5876907B2 (en) | Drugs for improving or treating dyslipidemia | |
JP4476479B2 (en) | Drugs for the treatment or prevention of diabetic complications | |
JP5345402B2 (en) | Composition for preventing or treating diseases related to thrombus or embolism | |
EP0195570B1 (en) | Pharmaceutical compositions | |
JP4746726B2 (en) | Composition of fenofibrate and vitamin E and its therapeutic use | |
KR20000049016A (en) | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid | |
US20140322314A1 (en) | Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment | |
JPH02243623A (en) | Therapy by fatty acid and aomposition thereof | |
JPH0249723A (en) | Encephalon function improving composition, learning ability enhancing agent, memory enhancing agent, preventive and remedy for dementia or functional food having encephalon function improving effect | |
AU2018229440A1 (en) | Administering compositions comprising docosapentaenoic acid | |
WO2014179341A1 (en) | Treatment with omega-3 fatty acid compositions | |
CA2905671A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
WO2014095628A1 (en) | Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa) | |
JP2010229099A (en) | Ameliorating or therapeutic drug for dyslipidemia | |
JPH07233062A (en) | Composition for treating skin pruritus of patient requiring artificial dialysis and composition for treating hyperparathyroidism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080825 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080825 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090825 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090825 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100825 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110825 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110825 Year of fee payment: 11 |